Probenecid potentiates MPTP/MPP+ toxicity by interference with cellular energy metabolism

Area of Science:

• Neuroscience
• Toxicology
• Biochemistry

Background:

• Probenecid is used with MPTP to model Parkinson's disease.
• The proposed mechanism involves probenecid increasing brain MPTP levels by reducing kidney excretion.
• Previous data questioned this mechanism, showing no change in MPP+ brain concentrations.

Purpose of the Study:

• Investigate the potentiating effects of probenecid on MPTP neurotoxicity.
• Examine the in vivo and in vitro mechanisms of probenecid's action.
• Determine if probenecid alters MPTP metabolism or renal elimination.

Main Methods:

• Administered probenecid with MPTP in a mouse model.
• Assessed neurotoxicity in dopaminergic and other neuronal populations.
• Measured intracellular ATP concentrations and effects of extracellular ATP.
• Tested probenecid's potentiation of other mitochondrial complex I inhibitors like rotenone.

Main Results:

• Probenecid exhibits toxicity to various neuronal populations, not just dopaminergic neurons.
• Probenecid potentiates the neurotoxic effects of other mitochondrial complex I inhibitors.
• Probenecid reduces intracellular ATP concentrations.
• The toxic effects of probenecid on neuronal cells are reversible with extracellular ATP.

Conclusions:

• Probenecid potentiates mitochondrial toxins through its impact on ATP metabolism.
• The mechanism does not involve altered MPTP metabolism or renal elimination.
• Probenecid's properties may be valuable for modeling atypical parkinsonian syndromes.